Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus MINOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus MINOCYCLINE HYDROCHLORIDE.
DEMECLOCYCLINE HYDROCHLORIDE vs MINOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Bacteriostatic antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
200 mg orally or intravenously once, followed by 100 mg every 12 hours; maximum 400 mg/day.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life: 11–17 hours (mean ~15 hours in normal renal function); prolonged to 18–30 hours in renal impairment; context: allows twice-daily dosing, but accumulation can occur in hepatic/renal dysfunction.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Renal (approximately 10% unchanged; higher in impaired renal function), biliary/fecal (major route via feces as unchanged drug and metabolites, up to 70% overall elimination through hepatobiliary system).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic